Prevention of High Altitude Pulmonary Edema
Phase 1
Completed
- Conditions
- High Altitude Pulmonary Edema
- Registration Number
- NCT00274430
- Lead Sponsor
- University of Zurich
- Brief Summary
A double-blind placebo controlled study
* To compare the effect of tadalafil and dexamethasone versus placebo on Ppa and pulmonary edema formation in subjects susceptible to HAPE.
* To investigate the effect of dexamethasone on alveolar fluid clearance, as assessed by measurement of the nasal potential difference, and prevention of HAPE.
* To investigate the effect of the tadalafil and dexamethasone versus placebo on the dynamic CBF autoregulation properties and on the development of AMS in HAPE susceptible subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- At least one previous episode of high altitude pulmonary edema
Exclusion Criteria
- pulmonary arterial hypertension
- congenital heart disease
- any chronic lung disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method prevention of high altitude pulmonary edema
- Secondary Outcome Measures
Name Time Method incidence of acute mountain sickness